Home/Pipeline/KP405

KP405

Parkinson's Disease

Pre-clinicalActive

Key Facts

Indication

Parkinson's Disease

Phase

Pre-clinical

Status

Active

Company

Kariya Pharmaceuticals

About Kariya Pharmaceuticals

Kariya Pharmaceuticals is a private, preclinical-stage biotech targeting a high-unmet need in neurodegenerative diseases with a novel dual incretin receptor agonist approach. Its lead asset, KP405, is positioned as a first-in-class, potentially superior therapy to existing incretin analogues, with completed GLP toxicology studies paving the way for Phase I trials. The company leverages strong scientific foundations from its CSO, a key opinion leader in neuroprotective incretin research, and strategic operational support from its CEO, who is an Executive-in-Residence at Novo Holdings. Backed by significant Danish institutional grants, Kariya aims to deliver a disease-modifying treatment for Parkinson's Disease.

View full company profile

Therapeutic Areas

Neurodegenerative Diseases Parkinson's Disease Alzheimer's Disease

Other Parkinson's Disease Drugs

Drug	Company	Phase	Status
NPT200-11	Neuropore Therapies	Phase 1	Partnered (UCB Pharma), status unclear
NUZ-001	Neurizon Therapeutics	Preclinical	Active
VXX-301	Vaxxinity	Preclinical	Pipeline
BAN2802	BioArctic	Phase 1	Active
CNM-Au8	Clene	Phase 2	Active
hpSC-Derived Neural/Dopaminergic Cells	International Stem Cell	Preclinical/Early Clinical	Inferred Active
SLS-004	Seelos Therapeutics	Preclinical	Research
SLS-007	Seelos Therapeutics	Preclinical	Research
Parkinson's Disease Portfolio (Platform-derived)	WD Pharmaceutical	Not Disclosed (Likely Preclinical/Early Clinical)	Active
UX-DA001	UniXell	Phase 1	Active, with trials ongoing in China and FDA IND cleared in U.S. (as of April 2025)
Parkinson's Disease Research	ProgenaBiome	Research	Active
A9 Dopaminergic Neuron Therapy	Trailhead Biosystems	Pre-clinical	Active